Chinese Academy of Medical Sciences
- Country
- 🇨🇳China
- Ownership
- Private, Subsidiary
- Established
- 2004-07-08
- Employees
- -
- Market Cap
- -
Phase II/III Study Comparing Chemoradiotherapy With Radiotherapy in Elderly Patients With Esophageal or Esophagogastric Cancer - 3JECROG P-01
- Conditions
- Radiotherapy; ComplicationsEsophagus CancerEsophagogastric Junction CancerChemoradiation
- Interventions
- Radiation: SIB-IMRT
- First Posted Date
- 2016-12-02
- Last Posted Date
- 2020-07-21
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 350
- Registration Number
- NCT02979691
- Locations
- 🇨🇳
Department of Radiation Oncology, Cancer Hospital, National Cancer Center, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medical College (PUMC), Beijing, China
Icotinib in Non-small Cell Lung Cancer Patients With Uncommon EGFR Mutation
- First Posted Date
- 2016-11-10
- Last Posted Date
- 2016-11-11
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 30
- Registration Number
- NCT02961270
- Locations
- 🇨🇳
Department of Medical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; Beijing Key Laboratory of Clinical Study on Anticancer Molecular Targeted Drugs, Beijing, China
High-dose Icotinib Treatment Beyond Progression in EGFR Mutant NSCLC
- First Posted Date
- 2016-11-09
- Last Posted Date
- 2016-11-18
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 25
- Registration Number
- NCT02960607
- Locations
- 🇨🇳
Chinese Academy of Medical Sciences, Beijing, China
The Study on the Pharmacokinetics of PEG-rhG-CSF in Children and Adolescents
- First Posted Date
- 2016-11-03
- Last Posted Date
- 2016-11-03
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 9
- Registration Number
- NCT02953730
- Locations
- 🇨🇳
Department of Pediatrics, Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
S1 Plus Docetaxel Versus Capecitabine Plus Docetaxel First-line Treatment in Patients With Advanced Breast Cancer
- Conditions
- Breast Cancer Recurrent
- Interventions
- Drug: S1 plus Docetaxel
- First Posted Date
- 2016-10-27
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT02947061
- Locations
- 🇨🇳
No.17 panjiayuannanli, Chaoyang District, Beijing, Beijing, China
Study of Preoperative Chemotherapy for Early Triple Negative or HER2-positive Operable Breast Cancer
- Conditions
- Breast Cancer
- Interventions
- Drug: Neoadjuvant ChemotherapyDrug: postoperative chemotherapy
- First Posted Date
- 2016-10-17
- Last Posted Date
- 2016-10-18
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 230
- Registration Number
- NCT02934828
- Locations
- 🇨🇳
Cancer Hospital & Institute Chinese Academy of Medical Sciences (CAMS), Beijing, Beijing, China
Simultaneous Integrated Boost Radiotherapy and Concurrent Nimotuzumab or Chemotherapy for Esophageal Carcinoma
- Conditions
- Esophageal Neoplasms
- Interventions
- Radiation: IMRT simultaneous integrated boostProcedure: Esophagectomy
- First Posted Date
- 2016-08-08
- Last Posted Date
- 2019-07-26
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT02858206
- Locations
- 🇨🇳
Zefen Xiao, Beijing, Beijing, China
Low -Dose-bevacizumab and Pemetrexed Versus TPC in Metastatic HER2-negative Breast Cancer Patients
- Conditions
- Metastatic Breast Cancer
- Interventions
- Drug: low-dose-bevacizumab/pemetrexedDrug: Treatment of physician's choice
- First Posted Date
- 2016-07-12
- Last Posted Date
- 2016-07-12
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 120
- Registration Number
- NCT02829008
- Locations
- 🇨🇳
Cancer Hospital, ChineseAMS, Beijing, Beijing, China
The Effect of Zhen Qi Shen Capsule Combined With Yu Yi Kang on Breast Cancer and Lung Cancer Patients With Chemotherapy
- Conditions
- Breast CancerLung Cancer
- Interventions
- Dietary Supplement: zhen qishen capsule and Oral Supplement of YuyikangDietary Supplement: zhen qishen capsule placebo and Oral Supplement of Yuyikang placeboRadiation: chemotherapyOther: nutrition education
- First Posted Date
- 2016-05-13
- Last Posted Date
- 2016-05-13
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 300
- Registration Number
- NCT02771756
- Locations
- 🇨🇳
National Cancer Institute, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
Study of Apatinib Combined With Oral Vinorelbine in Metastatic HER2 Negative Breast Cancer
- First Posted Date
- 2016-05-11
- Last Posted Date
- 2019-06-19
- Lead Sponsor
- Chinese Academy of Medical Sciences
- Target Recruit Count
- 40
- Registration Number
- NCT02768415
- Locations
- 🇨🇳
Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, Beijing, China